People · Operator
Named in public records as an officer, director or promoter · active 2009–2019 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lux Biosciences Inc | — | Biotechnology | Series B | $81.1M | $635.0M | 2009 |
| PanOptica, Inc. | — | Biotechnology | Series C | $57.3M | $1.7B | 2014 |
| Ophthotech Corp. | — | Biotechnology | Series B | $43.1M | $452.5M | 2018 |
| Praxis Precision Medicines, Inc. | — | Pharmaceuticals | Series B | $31.9M | $340.0M | 2019 |
| Gloucester Pharmaceuticals Inc | — | Biotechnology | Series B | $26.0M | $806.7M | 2009 |
Thomas Dyrberg at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Thomas Dyrberg on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Guyer | 3 | 8 |
| David Schnell | 2 | 7 |
| Lutz Giebel | 2 | 6 |
| Axel Bolte | 2 | 6 |
| Seth Harrison | 1 | 19 |
| Michael Ross | 1 | 18 |
| ABBIE CELNIKER | 1 | 6 |
| Nicholas Galakatos | 1 | 6 |
| Tracy Saxton | 1 | 5 |
| Kevin Starr | 1 | 5 |
| Colin Goddard | 1 | 5 |
| Bruce Peacock | 1 | 5 |
| WILLIAM D. YOUNG | 1 | 4 |
| Jay Moorin | 1 | 4 |
| Donald J Hayden | 1 | 3 |
| Nicholas C. Galakatos | 1 | 3 |
| Michael C. Ross | 1 | 3 |
| Alan B. Colowick | 1 | 3 |
| Martin Vogelbaum | 1 | 3 |
| Stefan Vitorovic | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.